These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 38783409)
21. Peanut allergy and oral immunotherapy. Lee TH; Chan JKC; Lau PC; Luk WP; Fung LH Hong Kong Med J; 2019 Jun; 25(3):228-234. PubMed ID: 31178442 [TBL] [Abstract][Full Text] [Related]
22. Monitoring Ara h 1, 2 and 3-sIgE and sIgG4 antibodies in peanut allergic children receiving oral rush immunotherapy. Nozawa A; Okamoto Y; Movérare R; Borres MP; Kurihara K Pediatr Allergy Immunol; 2014 Jun; 25(4):323-8. PubMed ID: 24953293 [TBL] [Abstract][Full Text] [Related]
23. Sustained outcomes in oral immunotherapy for peanut allergy (POISED study): a large, randomised, double-blind, placebo-controlled, phase 2 study. Chinthrajah RS; Purington N; Andorf S; Long A; O'Laughlin KL; Lyu SC; Manohar M; Boyd SD; Tibshirani R; Maecker H; Plaut M; Mukai K; Tsai M; Desai M; Galli SJ; Nadeau KC Lancet; 2019 Oct; 394(10207):1437-1449. PubMed ID: 31522849 [TBL] [Abstract][Full Text] [Related]
24. Extended boiling of peanut progressively reduces IgE allergenicity while retaining T cell reactivity. Tao B; Bernardo K; Eldi P; Chegeni N; Wiese M; Colella A; Kral A; Hayball J; Smith W; Forsyth K; Chataway T Clin Exp Allergy; 2016 Jul; 46(7):1004-14. PubMed ID: 27079163 [TBL] [Abstract][Full Text] [Related]
25. Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy. Vickery BP; Scurlock AM; Kulis M; Steele PH; Kamilaris J; Berglund JP; Burk C; Hiegel A; Carlisle S; Christie L; Perry TT; Pesek RD; Sheikh S; Virkud Y; Smith PB; Shamji MH; Durham SR; Jones SM; Burks AW J Allergy Clin Immunol; 2014 Feb; 133(2):468-75. PubMed ID: 24361082 [TBL] [Abstract][Full Text] [Related]
26. A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response. Varshney P; Jones SM; Scurlock AM; Perry TT; Kemper A; Steele P; Hiegel A; Kamilaris J; Carlisle S; Yue X; Kulis M; Pons L; Vickery B; Burks AW J Allergy Clin Immunol; 2011 Mar; 127(3):654-60. PubMed ID: 21377034 [TBL] [Abstract][Full Text] [Related]
27. Efficacy and Safety of AR101 in Oral Immunotherapy for Peanut Allergy: Results of ARC001, a Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial. Bird JA; Spergel JM; Jones SM; Rachid R; Assa'ad AH; Wang J; Leonard SA; Laubach SS; Kim EH; Vickery BP; Davis BP; Heimall J; Cianferoni A; MacGinnitie AJ; Crestani E; Burks AW; J Allergy Clin Immunol Pract; 2018; 6(2):476-485.e3. PubMed ID: 29092786 [TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of oral immunotherapy in children aged 1-3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study. Jones SM; Kim EH; Nadeau KC; Nowak-Wegrzyn A; Wood RA; Sampson HA; Scurlock AM; Chinthrajah S; Wang J; Pesek RD; Sindher SB; Kulis M; Johnson J; Spain K; Babineau DC; Chin H; Laurienzo-Panza J; Yan R; Larson D; Qin T; Whitehouse D; Sever ML; Sanda S; Plaut M; Wheatley LM; Burks AW; Lancet; 2022 Jan; 399(10322):359-371. PubMed ID: 35065784 [TBL] [Abstract][Full Text] [Related]
29. Successful oral tolerance induction in severe peanut allergy. Clark AT; Islam S; King Y; Deighton J; Anagnostou K; Ewan PW Allergy; 2009 Aug; 64(8):1218-20. PubMed ID: 19226304 [TBL] [Abstract][Full Text] [Related]
30. Administration of a probiotic with peanut oral immunotherapy: A randomized trial. Tang ML; Ponsonby AL; Orsini F; Tey D; Robinson M; Su EL; Licciardi P; Burks W; Donath S J Allergy Clin Immunol; 2015 Mar; 135(3):737-44.e8. PubMed ID: 25592987 [TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of oral immunotherapy with AR101 in European children with a peanut allergy (ARTEMIS): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial. O'B Hourihane J; Beyer K; Abbas A; Fernández-Rivas M; Turner PJ; Blumchen K; Nilsson C; Ibáñez MD; Deschildre A; Muraro A; Sharma V; Erlewyn-Lajeunesse M; Zubeldia JM; De Blay F; Sauvage CD; Byrne A; Chapman J; Boralevi F; DunnGalvin A; O'Neill C; Norval D; Vereda A; Skeel B; Adelman DC; du Toit G Lancet Child Adolesc Health; 2020 Oct; 4(10):728-739. PubMed ID: 32702315 [TBL] [Abstract][Full Text] [Related]
32. Safety of a peanut oral immunotherapy protocol in children with peanut allergy. Hofmann AM; Scurlock AM; Jones SM; Palmer KP; Lokhnygina Y; Steele PH; Kamilaris J; Burks AW J Allergy Clin Immunol; 2009 Aug; 124(2):286-91, 291.e1-6. PubMed ID: 19477496 [TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of high-dose peanut oral immunotherapy with factors predicting outcome. Anagnostou K; Clark A; King Y; Islam S; Deighton J; Ewan P Clin Exp Allergy; 2011 Sep; 41(9):1273-81. PubMed ID: 21414048 [TBL] [Abstract][Full Text] [Related]
34. Blocking antibodies induced by peanut oral and sublingual immunotherapy suppress basophil activation and are associated with sustained unresponsiveness. Orgel K; Burk C; Smeekens J; Suber J; Hardy L; Guo R; Burks AW; Kulis M Clin Exp Allergy; 2019 Apr; 49(4):461-470. PubMed ID: 30383313 [TBL] [Abstract][Full Text] [Related]
35. First Real-World Safety Analysis of Preschool Peanut Oral Immunotherapy. Soller L; Abrams EM; Carr S; Kapur S; Rex GA; Leo S; Lidman PG; Yeung J; Vander Leek TK; McHenry M; Wong T; Cook VE; Hildebrand KJ; Gerstner TV; Mak R; Lee NJ; Cameron SB; Chan ES J Allergy Clin Immunol Pract; 2019; 7(8):2759-2767.e5. PubMed ID: 31002957 [TBL] [Abstract][Full Text] [Related]